Estradiol

Generic Name
Estradiol
Brand Names
Activella 1/0.5 28 Day, Activelle, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Etyqa 0.5/0.1 28 Day, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem
Drug Type
Small Molecule
Chemical Formula
C18H24O2
CAS Number
50-28-2
Unique Ingredient Identifier
4TI98Z838E
Background

Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays,...

Indication

Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (...

Associated Conditions
Atrophic Vaginitis, Breast Cancer, Breast engorgement caused by Postpartum state, Heavy Menstrual Bleeding, Hypogonadism female, Kraurosis Vulvae, Metastatic Breast Cancer, Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure (POF), Prostate Cancer, Severe Pain, Urogenital atrophy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Advanced androgen dependent Prostate cancer, Female castration, Hypoestrogenism
Associated Therapies
Contraception, Hormone Replacement Therapy, Palliative Treatment
Clinical Trials
Related News

Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: Estradiol
First Posted Date
2006-05-10
Last Posted Date
2015-02-16
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
66
Registration Number
NCT00324259
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

and more 4 locations

Prostate Adenocarcinoma TransCutaneous Hormones

First Posted Date
2006-03-17
Last Posted Date
2020-11-27
Lead Sponsor
University College, London
Target Recruit Count
2200
Registration Number
NCT00303784
Locations
🇬🇧

Walsgrave Hospital, Coventry, England, United Kingdom

🇬🇧

Mayday University Hospital, Croydon, England, United Kingdom

🇬🇧

Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom

and more 29 locations

Effects of Tibolone Treatment on the Endometrium

Phase 4
Completed
Conditions
Postmenopause
Osteoporosis
First Posted Date
2006-02-22
Last Posted Date
2006-02-22
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
35
Registration Number
NCT00294463
Locations
🇳🇱

Erasmus MC, Rotterdam, Netherlands

Effect of Estrogen & Stress for Postmenopausal Women

Phase 2
Completed
Conditions
Aging
First Posted Date
2005-09-22
Last Posted Date
2007-02-27
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
40
Registration Number
NCT00220454

Clinical Estradiol Trial in Women With Schizophrenia

First Posted Date
2005-09-21
Last Posted Date
2015-02-04
Lead Sponsor
Bayside Health
Target Recruit Count
100
Registration Number
NCT00206570
Locations
🇦🇺

Bayside Health - The Alfred Hospital, Melbourne, Victoria, Australia

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

Phase 4
Completed
Conditions
Postmenopausal Symptoms
Interventions
Other: Placebo
Drug: Estrogel
First Posted Date
2005-09-12
Last Posted Date
2022-09-13
Lead Sponsor
ASCEND Therapeutics
Target Recruit Count
221
Registration Number
NCT00160173
Locations
🇺🇸

Site 93, Atlanta, Georgia, United States

🇺🇸

Site 36, Aventura, Florida, United States

🇺🇸

Site 11, Baltimore, Maryland, United States

and more 106 locations

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

Phase 4
Completed
Conditions
Turner Syndrome
Interventions
Drug: estradiol
First Posted Date
2005-08-25
Last Posted Date
2013-06-14
Lead Sponsor
Line Cleemann
Target Recruit Count
43
Registration Number
NCT00134745
Locations
🇩🇰

Pediatric Unit, Hillerod Hospital, Hillerod, Frederiksborg County, Denmark

POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis

First Posted Date
2005-08-05
Last Posted Date
2011-12-30
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
300
Registration Number
NCT00127075
Locations
🇫🇷

Hôpital Pierre Wertheimer, Bron, France

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

Phase 1
Terminated
Conditions
HIV Infections
First Posted Date
2002-09-09
Last Posted Date
2015-06-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
120
Registration Number
NCT00044837
Locations
🇺🇸

Barbara Brizz, Rockville, Maryland, United States

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Not Applicable
Completed
Conditions
Systemic Lupus Erythematosus
First Posted Date
2000-08-04
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
970
Registration Number
NCT00006133
Locations
🇺🇸

Louisiana State University School of Medicine, Shreveport, Louisiana, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Pritzker School of Medicine, Chicago, Illinois, United States

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy